Angioedema

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA withdrawal · 2009-12-31
EMA Refused: Rhucin (recombinant human C1-inhibitor) — Pharming Group N.V.
The EMA refused approval for Rhucin (recombinant human C1-inhibitor) by Pharming Group N.V. for angioedema, decision dated 31 December 2009.